Keytruda Plus Chemotherapy Is Not Superior to Chemotherapy Alone in Metastatic Prostate Cancer

Keytruda plus chemotherapy failed to best the chemotherapy docetaxel alone in patients with metastatic castration-resistant prostate cancer, according to findings of a study of more than 1,000 ... read more

Keytruda-Lenvima Combo Fails to Top Lenvima Alone in Patients With Unresectable Liver Cancer

Treatment with Keytruda plus Lenvima did not best Lenvima alone as a first-line treatment option for a group of patients with liver cancer that could not be treated with surgery, according to recently ... read more

AstraZeneca, Daiichi Sankyo drug, Keytruda combo shows promise in early stage lung cancer trial

AstraZeneca (AZN) and Daiichi Sankyo's (DSKYF) (DSNKY) said their medicine datopotamab deruxtecan (Dato-DXd) in combination with Merck's (MRK) Keytruda (pembrolizumab) with ... read more

Keytruda fluffs its lines in prostate, liver cancer trials

Double blow for Merck as Keytruda fails a pair of phase 3 trials in metastatic castration-resistant prostate cancer and unresectable hepatocellular carcinoma ... read more

Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern

Amgen Inc (NASDAQ: AMGN) announced new data sets from its thoracic oncology portfolio, including new combination study results, including Lumakras (sotorasib) with pembrolizumab or atezolizumab and ... read more

Merck avoided billions in U.S. tax by offshoring Keytruda profits - senator

Drugmaker Merck & Co avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, ... read more

Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal

Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for ... read more

Merck profit tops Wall Street view on strong Keytruda sales

Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer immunotherapy drug. read more

Merck phase 3 KEYNOTE-921 trial of Keytruda plus chemotherapy in patients with mCRPC fails to meet dual primary endpoints

Merck phase 3 KEYNOTE-921 trial of Keytruda plus chemotherapy in patients with mCRPC fails to meet dual primary endpoints: Rahway, New Jersey Thursday, August 4, 2022, 09:00 Hrs [ ... read more

Merck on backfoot as blockbuster Keytruda fails another phase 3 study, this time in prostate cancer

Merck (MRK) blockbuster drug Keytruda did not meet the main goals of overall survival ((OS)) and radiographic progression-free survival ((rPFS)) in a phase 3 trial in certain ... read more

Related Blogs:

Keytruda Survival Cancer Blockbuster Progression Radiographic Chemotherapy Certain Of overall Treatment Patients Radiographic Progression Of overall Survival Goals Of overall Goals Of overall Survival

Real Time RSS Feeds | Disclaimer | Contact Us